- Home
- Publications
- Publication Search
- Publication Details
Title
Antisense Technology: A Review
Authors
Keywords
antisense, RNase H1, splicing, molecular mechanisms, clinical results
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume -, Issue -, Pages 100416
Publisher
Elsevier BV
Online
2021-02-18
DOI
10.1016/j.jbc.2021.100416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 100 years of modelling ligand–receptor binding and response: A focus on GPCRs
- (2020) David B. Finlay et al. BRITISH JOURNAL OF PHARMACOLOGY
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
- (2020) Diane E. Frank et al. NEUROLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
- (2020) Michael E Østergaard et al. NUCLEIC ACIDS RESEARCH
- Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia
- (2020) PadmaKumar Narayanan et al. Nucleic Acid Therapeutics
- Phosphorothioate modified oligonucleotide–protein interactions
- (2020) Stanley T Crooke et al. NUCLEIC ACIDS RESEARCH
- Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context
- (2020) Stanley T. Crooke et al. BIOCHEMICAL PHARMACOLOGY
- The Interaction of Phosphorothioate Containing RNA Targeted Drugs with Proteins is a Critical Determinant of The Therapeutic Effects of These Agents
- (2020) Stanley Crooke et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
- (2020) Alexandre J. Debacker et al. MOLECULAR THERAPY
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms
- (2020) Adam J. Pollak et al. Nucleic Acid Therapeutics
- Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- (2020) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
- (2020) Daniel Gaudet et al. EUROPEAN HEART JOURNAL
- Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
- (2020) Danny M. Cohn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity
- (2020) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
- (2019) Jason D. Ferrone et al. Nucleic Acid Therapeutics
- Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
- (2019) Maja M Janas et al. NUCLEIC ACIDS RESEARCH
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
- (2019) Erin S. Morgan et al. DIABETES CARE
- RNA-Targeted Therapeutics
- (2019) Stanley T. Crooke et al. Cell Metabolism
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
- (2019) Wen Shen et al. NATURE BIOTECHNOLOGY
- Targeting Huntingtin Expression in Patients with Huntington’s Disease
- (2019) Sarah J. Tabrizi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
- (2019) Michael E Østergaard et al. NUCLEIC ACIDS RESEARCH
- Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
- (2019) Michael T Migawa et al. NUCLEIC ACIDS RESEARCH
- Current Development of siRNA Bioconjugates: From Research to the Clinic
- (2019) Ivan V. Chernikov et al. Frontiers in Pharmacology
- Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
- (2019) C. Frank Bennett et al. Annual Review of Neuroscience
- Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
- (2019) Lindsay N. Alfano et al. MEDICINE
- Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
- (2019) Thazha P Prakash et al. NUCLEIC ACIDS RESEARCH
- mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
- (2019) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
- (2019) Shiyu Wang et al. Nucleic Acid Therapeutics
- Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis
- (2019) Nicholas J. Viney et al. JOURNAL OF CARDIAC FAILURE
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
- (2019) Darryl C. De Vivo et al. NEUROMUSCULAR DISORDERS
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly
- (2019) Ying Wang et al. Nucleic Acid Therapeutics
- RNA toxicity in non‐coding repeat expansion disorders
- (2019) Bart Swinnen et al. EMBO JOURNAL
- O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
- (2019) K. Wagner et al. NEUROMUSCULAR DISORDERS
- Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
- (2019) Timothy A Vickers et al. NUCLEIC ACIDS RESEARCH
- Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
- (2019) Xiangjun Tang et al. Frontiers in Oncology
- Mongersen (GED-0301) for Active Crohnʼs Disease
- (2019) Bruce E. Sands et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes
- (2019) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B Rx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
- (2018) Andres Digenio et al. DIABETES CARE
- Locked nucleic acid: modality, diversity, and drug discovery
- (2018) Peter H. Hagedorn et al. DRUG DISCOVERY TODAY
- A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
- (2018) Peter J Trainer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Discovery and development of new antibacterial drugs: learning from experience?
- (2018) Nicole Jackson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
- (2018) Wen Shen et al. NUCLEIC ACIDS RESEARCH
- Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
- (2018) Shiyu Wang et al. NUCLEIC ACIDS RESEARCH
- The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice
- (2018) Chenguang Zhao et al. Journal of Cystic Fibrosis
- COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
- (2018) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells
- (2018) Jonathan W. Kotula et al. Nucleic Acid Therapeutics
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Next-Generation Sequencing Technologies
- (2018) W. Richard McCombie et al. Cold Spring Harbor Perspectives in Medicine
- Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
- (2018) Shiyu Wang et al. Molecular Therapy-Nucleic Acids
- The Discovery of Insulin: An Important Milestone in the History of Medicine
- (2018) Ignazio Vecchio et al. Frontiers in Endocrinology
- Targeted delivery of antisense oligonucleotides to pancreatic β-cells
- (2018) C. Ämmälä et al. Science Advances
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Entering the Modern Era of Gene Therapy
- (2018) Xavier M. Anguela et al. Annual Review of Medicine
- Alicaforsen for the treatment of inflammatory bowel disease
- (2017) Vipul Jairath et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy
- (2017) Xingxing Wu et al. HUMAN MOLECULAR GENETICS
- Alicaforsen in the treatment of pouchitis
- (2017) Thomas Greuter et al. Immunotherapy
- RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
- (2017) A. Robert MacLeod et al. JOURNAL OF CLINICAL PHARMACOLOGY
- RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
- (2017) Xue-Hai Liang et al. MOLECULAR THERAPY
- Cellular uptake and trafficking of antisense oligonucleotides
- (2017) Stanley T Crooke et al. NATURE BIOTECHNOLOGY
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of base stacking on the conformations and electrostatics of single-stranded DNA
- (2017) Alex Plumridge et al. NUCLEIC ACIDS RESEARCH
- Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
- (2017) Xue-Hai Liang et al. NUCLEIC ACIDS RESEARCH
- Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
- (2017) Michael Tanowitz et al. NUCLEIC ACIDS RESEARCH
- Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
- (2017) Jayaprakash K. Nair et al. NUCLEIC ACIDS RESEARCH
- Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
- (2017) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
- (2017) Jeffrey K. Bailey et al. NUCLEIC ACIDS RESEARCH
- The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides
- (2017) Suzanne Paz et al. Nucleic Acid Therapeutics
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Molecular Mechanisms of Antisense Oligonucleotides
- (2017) Stanley T. Crooke Nucleic Acid Therapeutics
- First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
- (2017) Norbert Pfeiffer et al. PLoS One
- Transcriptomic analysis of the role of RasGEF1B circular RNA in the TLR4/LPS pathway
- (2017) Wei Lun Ng et al. Scientific Reports
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
- (2016) K. N. Chi et al. ANNALS OF ONCOLOGY
- A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
- (2016) S. Chowdhury et al. EUROPEAN JOURNAL OF CANCER
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
- (2016) Stanley T Crooke et al. MOLECULAR THERAPY
- Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
- (2016) Xue-hai Liang et al. NATURE BIOTECHNOLOGY
- ViableRNaseH1knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function
- (2016) Walt F. Lima et al. NUCLEIC ACIDS RESEARCH
- Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
- (2016) Xue-Hai Liang et al. NUCLEIC ACIDS RESEARCH
- RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
- (2016) Walt F. Lima et al. NUCLEIC ACIDS RESEARCH
- Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
- (2016) Colton M. Miller et al. NUCLEIC ACIDS RESEARCH
- Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions
- (2016) Timothy A. Vickers et al. PLoS One
- Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
- (2016) Nathalie M. Goemans et al. PLoS One
- Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
- (2015) Richard S. Geary et al. ADVANCED DRUG DELIVERY REVIEWS
- Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
- (2015) Mark J. Graham et al. JOURNAL OF LIPID RESEARCH
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Spinal Muscular Atrophy
- (2015) Stephen J. Kolb et al. NEUROLOGIC CLINICS
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
- (2015) Harry R. Büller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
- (2015) Daniela Castanotto et al. NUCLEIC ACIDS RESEARCH
- Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
- (2015) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
- (2015) Timothy A. Vickers et al. NUCLEIC ACIDS RESEARCH
- Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
- (2015) Sebastien A. Burel et al. NUCLEIC ACIDS RESEARCH
- 2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
- (2015) Wen Shen et al. NUCLEIC ACIDS RESEARCH
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs
- (2015) Hartmut Jahns et al. Nature Communications
- Substitution of tryptophan 89 with tyrosine switches the DNA binding mode of PC4
- (2015) Jinguang Huang et al. Scientific Reports
- Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
- (2014) Meike H. van der Ree et al. ANTIVIRAL RESEARCH
- The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia
- (2014) Mary P McGowan et al. Clinical Lipidology
- Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
- (2014) Robert A. Fey et al. INHALATION TOXICOLOGY
- Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
- (2014) Thomas Voit et al. LANCET NEUROLOGY
- CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
- (2014) V. Limmroth et al. NEUROLOGY
- Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
- (2014) W. Brad Wan et al. NUCLEIC ACIDS RESEARCH
- Phosphorothioate oligonucleotides can displaceNEAT1RNA and form nuclear paraspeckle-like structures
- (2014) Wen Shen et al. NUCLEIC ACIDS RESEARCH
- TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells
- (2014) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
- (2014) Walt F. Lima et al. PLoS One
- Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
- (2014) Timothy A. Vickers et al. PLoS One
- Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
- (2014) Timothy A. Vickers et al. PLoS One
- Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
- (2014) JoAnn D. Flaim et al. Journal of the American Heart Association
- Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells
- (2013) Xue-hai Liang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- (2013) D Bianchini et al. BRITISH JOURNAL OF CANCER
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
- (2013) Lars Petter Jordheim et al. NATURE REVIEWS DRUG DISCOVERY
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
- (2013) Michael E. Østergaard et al. NUCLEIC ACIDS RESEARCH
- Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9
- (2013) Ekambar R. Kandimalla et al. NUCLEIC ACIDS RESEARCH
- Gene Expression Regulation by Upstream Open Reading Frames and Human Disease
- (2013) Cristina Barbosa et al. PLoS Genetics
- Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
- (2012) Dongbo Yu et al. CELL
- Single-Stranded siRNAs Activate RNAi in Animals
- (2012) Walt F. Lima et al. CELL
- The Nicotinic Acetylcholine Receptor: The Founding Father of the Pentameric Ligand-gated Ion Channel Superfamily
- (2012) Jean-Pierre Changeux JOURNAL OF BIOLOGICAL CHEMISTRY
- Unique Gene-Silencing and Structural Properties of 2′-Fluoro-Modified siRNAs
- (2011) Muthiah Manoharan et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP
- (2011) Timothy A. Vickers et al. NUCLEIC ACIDS RESEARCH
- Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
- (2010) H. Zhang et al. BLOOD
- An Upstream Open Reading Frame and the Context of the Two AUG Codons Affect the Abundance of Mitochondrial and Nuclear RNase H1
- (2010) Y. Suzuki et al. MOLECULAR AND CELLULAR BIOLOGY
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- (2009) Aimee L. Jackson et al. NATURE REVIEWS DRUG DISCOVERY
- Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1
- (2009) Timothy A. Vickers et al. NUCLEIC ACIDS RESEARCH
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Discovery of Innovative Small Molecule Therapeutics
- (2008) Magid Abou-Gharbia JOURNAL OF MEDICINAL CHEMISTRY
- Oral Delivery of Antisense Oligonucleotides in Man
- (2007) Lloyd G. Tillman et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now